Personal Finance. Credit Cards. About Us. Who Is the Motley Fool? Fool Podcasts. New Ventures. Search Search:. Sep 26, at AM. Author Bio Keith began writing for the Fool in and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow keithspeights. However, the company has other drugs and promising pipeline candidates. BMS stock could be a good choice for long-term investors willing to wait for growth. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Join Stock Advisor Discounted offers are only available to new members. Quotes delayed at least 20 minutes. Market data provided by Ticker Tech. Powered and implemented by Ticker Tech. Investor Resources. Our testing substantiates this with the optimum range for price performance between It is the most commonly used metric for determining a company's value relative to its earnings.
In this example, we are using the consensus earnings estimate for the Current Fiscal Year F1. In general, a lower number or multiple is usually considered better that a higher one.
In general, the lower the ratio is the better. It's calculated as earnings divided by price. A yield of 8. The most common way this ratio is used is to compare it to other stocks and to compare it to the 10 Year T-Bill.
Conversely, if the yield on stocks is higher than the 10 Yr. Since bonds and stocks compete for investors' dollars, a higher yield typically needs to be paid to the stock investor for the extra risk being assumed vs.
It is used to help gauge a company's financial health. A higher number means the company has more debt to equity, whereas a lower number means it has less debt to equity.
When comparing this ratio to different stocks in different industries, take note that some businesses are more capital intensive than others. So it's a good idea to compare a stock's debt to equity ratio to its industry to see how it stacks up to its peers first.
Cash flow can be found on the cash flow statement. It's then divided by the number of shares outstanding to determine how much cash is generated per share. It's used by investors as a measure of financial health.
Cash is vital to a company in order to finance operations, invest in the business, pay expenses, etc. Since cash can't be manipulated like earnings can, it's a preferred metric for analysts.
Using this item along with the 'Current Cash Flow Growth Rate' in the Growth category above , and the 'Price to Cash Flow ratio' several items above in this same Value category , will give you a well-rounded indication of the amount of cash they are generating, the rate of their cash flow growth, and the stock price relative to its cash flow.
This longer-term historical perspective lets the user see how a company has grown over time. Note: there are many factors that can influence the longer-term number, not the least of which is the overall state of the economy recession will reduce this number for example, while a recovery will inflate it , which can skew comparisons when looking out over shorter time frames.
The longer-term perspective helps smooth out short-term events. Projected EPS Growth looks at the estimated growth rate for one year. It takes the consensus estimate for the current fiscal year F1 divided by the EPS for the last completed fiscal year F0 actual if reported, the consensus if not. That does not mean that all companies with large growth rates will have a favorable Growth Score. Many other growth items are considered as well.
But, typically, an aggressive growth trader will be interested in the higher growth rates. Cash Flow is net income plus depreciation and other non-cash charges. A strong cash flow is important for covering interest payments, particularly for highly leveraged companies. Cash Flow is a measurement of a company's health. It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio.
In this case, it's the cash flow growth that's being looked at. A positive change in the cash flow is desired and shows that more 'cash' is coming in than 'cash' going out. The Historical Cash Flow Growth is the longer-term year annualized growth rate of the cash flow change. Once again, cash flow is net income plus depreciation and other non-cash charges.
Cash flow itself is an important item on the income statement. While the one year change shows the current conditions, the longer look-back period shows how this metric has changed over time and helps put the current reading into proper perspective. Also, by looking at the rate of this item, rather than the actual dollar value, it makes for easier comparisons across the industry and peers. The Current Ratio is defined as current assets divided by current liabilities.
It measures a company's ability to pay short-term obligations. It's also commonly referred to as a 'liquidity ratio'. A ratio of 1 means a company's assets are equal to its liabilities. Less than 1 means its liabilities exceed its short-term assets cash, inventory, receivables, etc. Above 1 means it assets are greater than its liabilities. A ratio of 2 means its assets are twice that of its liabilities. A higher number is better than a lower number. A 'good' number would usually fall within the range of 1.
Like most ratios, this number will vary from industry to industry. This measure is expressed as a percentage. Also, you can understand how Bristol Myers Squibb revenues have changed over the years along with trends in revenues for its closest peers in a separate dashboard analysis. Pharmaceutical companies are impacted by the current pandemic, which has resulted in lower sales for drugs.
That said, the sales have begun to rebound over the recent quarters. But now, given the recent decline, will BMY stock continue its downward trajectory over the coming weeks, or is a recovery in the stock imminent? Abecma was also approved by the U. FDA in March earlier this year.
Recently, the company has also filed for a supplemental biologics license application with the US FDA for its blockbuster drug, Orencia, currently approved for certain forms of arthritis. Bristol Myers Squibb is now seeking approval for the prevention of moderate to severe acute graft versus host disease aGvHD. The newly filed application is under priority review with a decision likely later this year.
0コメント